APA (7th ed.) Citation

K, M., JJ, P., A, A., M, M., W, G., KL, B., . . . J, P. (2020). The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood advances, 4(13), 3072. https://doi.org/10.1182/bloodadvances.2020001800

Chicago Style (17th ed.) Citation

K, Maharaj, et al. "The Dual PI3Kδ/CK1ε Inhibitor Umbralisib Exhibits Unique Immunomodulatory Effects on CLL T Cells." Blood Advances 4, no. 13 (2020): 3072. https://doi.org/10.1182/bloodadvances.2020001800.

MLA (9th ed.) Citation

K, Maharaj, et al. "The Dual PI3Kδ/CK1ε Inhibitor Umbralisib Exhibits Unique Immunomodulatory Effects on CLL T Cells." Blood Advances, vol. 4, no. 13, 2020, p. 3072, https://doi.org/10.1182/bloodadvances.2020001800.